Lineage Cell Therapeutics, Inc. Research And Development Expense

• Lineage Cell Therapeutics, Inc. showed an increase of +42.2% in Research And Development Expense from 2024 to 2025.
• This data is from Lineage Cell Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
• XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 17 years of available data (2009 to 2025), Lineage Cell Therapeutics, Inc.'s Research And Development Expense has grown by 657.2%.
• Historical annual values: Fiscal year 2025: $17.73 million | Fiscal year 2024: $12.47 million | Fiscal year 2023: $15.71 million | Fiscal year 2022: $13.99 million | Fiscal year 2021: $33.91 million | Fiscal year 2020: $12.32 million | Fiscal year 2019: $17.95 million | Fiscal year 2018: $20.96 million | Fiscal year 2017: $24.02 million | Fiscal year 2016: $36.11 million | Fiscal year 2015: $42.60 million | Fiscal year 2014: $37.53 million | Fiscal year 2013: $26.61 million | Fiscal year 2012: $18.12 million | Fiscal year 2011: $13.70 million | Fiscal year 2010: $8.19 million | Fiscal year 2009: -$3.18 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026